{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:45:27Z","timestamp":1792615527343,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1097\/md.0000000000008142","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T16:21:01Z","timestamp":1506529261000},"page":"e8142","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of escitalopram monotherapy in the treatment of major depressive disorder"],"prefix":"10.1097","volume":"96","author":[{"given":"Guanjun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-42-20210309","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R3-42-20210309","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.4088\/JCP.9078tx1c","article-title":"A review of the current guidelines for depression treatment","volume":"71","author":"Gelenberg","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R4-42-20210309","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.npp.1300571","article-title":"Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy","volume":"30","author":"Lieberman","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R5-42-20210309","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/13651500410005496","article-title":"Escitalopram: a unique mechanism of action","volume":"8","author":"Braestrup","year":"2004","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R6-42-20210309","first-page":"3","article-title":"Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter - a review of current understanding of its mechanism of action.","volume":"1-","author":"Zhong","year":"2012","journal-title":"Psychopharmacology"},{"key":"R7-42-20210309","doi-asserted-by":"crossref","first-page":"668","DOI":"10.12968\/hosp.2002.63.11.1912","article-title":"Escitalopram: efficacy and tolerability in the treatment of depression","volume":"63","author":"Baldwin","year":"2002","journal-title":"Hosp Med"},{"key":"R8-42-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.yic.0000074988.54339.7c","article-title":"Escitalopram (10\u201320\u200amg\/day) is effective and well tolerated in a placebo-controlled study in depression in primary care","volume":"18","author":"Lepola","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"R9-42-20210309","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.euroneuro.2008.12.003","article-title":"Superiority of escitalopram to paroxetine in the treatment of depression","volume":"19","author":"Kasper","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R10-42-20210309","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200609000-00008","article-title":"Escitalopram versus venlafaxine XR in the treatment of depression","volume":"21","author":"Montgomery","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R11-42-20210309","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R12-42-20210309","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/030079907X188107","article-title":"Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder","volume":"23","author":"Pigott","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R13-42-20210309","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007995.2010.529430","article-title":"Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences","volume":"26","author":"Sicras-Mainar","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R14-42-20210309","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1742-1241.2005.00440.x","article-title":"Efficacy of escitalopram in patients with severe depression: a pooled analysis","volume":"59","author":"Llorca","year":"2005","journal-title":"Int J Clin Pract"},{"key":"R15-42-20210309","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1185\/03007990802622726","article-title":"Escitalopram in the treatment of major depressive disorder: a meta-analysis","volume":"25","author":"Kennedy","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R16-42-20210309","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/YIC.0b013e32833948d8","article-title":"Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis","volume":"25","author":"Lam","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"R17-42-20210309","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S146114571000115X","article-title":"Efficacy of escitalopram compared to citalopram: a meta-analysis","volume":"14","author":"Montgomery","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R18-42-20210309","first-page":"901","article-title":"Comparison of escitalopram with citalopram in treatment of depression: a randomized, double-blind, multicenter study","volume":"30","author":"Shen","year":"2012","journal-title":"Chin J New Drugs Clin Rem"},{"key":"R19-42-20210309","first-page":"300","article-title":"Randomized double-blind controlled trial of escitalopram versus citalopram in the treatment of depression","volume":"22","author":"Chen","year":"2010","journal-title":"Shanghai Arch Psychiatry"},{"key":"R20-42-20210309","first-page":"425","article-title":"[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the \u201cBoulenger\u201d study]","volume":"36","author":"Chauvet-Gelinier","year":"2010","journal-title":"Encephale"},{"key":"R21-42-20210309","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R22-42-20210309","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/030079907X188107","article-title":"Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder","volume":"23","author":"Pigott","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R23-42-20210309","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2006-946702","article-title":"Effective dose of escitalopram in moderate versus severe DSM-IV major depression","volume":"39","author":"Bech","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"R24-42-20210309","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s11011-017-9992-5","article-title":"Efficacy and safety of escitalopram in treatment of severe depression in Chinese population","volume":"32","author":"Si","year":"2017","journal-title":"Metab Brain Dis"},{"key":"R25-42-20210309","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1345\/aph.1K089","article-title":"Escitalopram therapy for major depression and anxiety disorders","volume":"41","author":"Baldwin","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R26-42-20210309","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/da.20141","article-title":"Escitalopram in the treatment of anxiety symptoms associated with depression","volume":"24","author":"Bandelow","year":"2007","journal-title":"Depress Anxiety"},{"key":"R27-42-20210309","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/NDT.S120190","article-title":"Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population","volume":"13","author":"Jiang","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R28-42-20210309","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1185\/03007990903482467","article-title":"Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine","volume":"26","author":"Boulenger","year":"2010","journal-title":"Curr Med Res Opin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:34:42Z","timestamp":1620959682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201709290-00042"}},"subtitle":["A pooled analysis of 4 Chinese clinical trials"],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":27,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008142","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}